Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Colorectal cancer screening: An update to the American Cancer Society guideline, 2026.

CA: a cancer journal for clinicians·2026
Same author

An exploratory mixed-methods study using the ELICIT framework to identify stakeholder-informed implementation strategies for a population health platform.

BMC health services research·2026
Same author

Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

The ENGAGE study: a randomized trial optimizing uptake of germline cancer genetic services in childhood cancer survivors.

Lancet regional health. Americas·2026
Same author

Economic Evaluation of GARDE: A Digital Health Platform for Population-Level Hereditary Cancer Risk Assessment.

JCO oncology practice·2026
Same author

Supplemental Magnetic Resonance Imaging in Breast Cancer Screening: The Challenge of Using Wisely.

Annals of internal medicine·2026
Same journal

Preventing Postpartum Pelvic Floor Dysfunction: Clinical Evidence and Policy Gaps in U.S. Coverage of Pelvic Floor Muscle Therapy.

Urology·2026
Same journal

Editorial Comment on "Through the Eyes of the Applicant: A Qualitative Study of the Urology Residency Match".

Urology·2026
Same journal

Editorial Comment on "A Histopathologic Assessment of Prostate Ductal Anatomy in Relation to Micro-Ultrasound".

Urology·2026
Same journal

Same-Day Discharge Following Multiport Robot-Assisted Simple Prostatectomy: A Prospective Feasibility Study of Outcomes, Costs, and Post-Discharge Healthcare Utilization.

Urology·2026
Same journal

Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer.

Urology·2026
Same journal

Intractable Epistaxis and Severe Hypertension in a Young Woman.

Urology·2026
See all related articles

Related Experiment Video

Updated: May 30, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

Ethnic differences in bladder cancer survival.

David S Yee1, Nicole M Ishill, William T Lowrance

  • 1Department of Surgery, University of Utah, Salt Lake City, Utah, USA. yeed1@sutterhealth.org

Urology
|July 26, 2011
PubMed
Summary
This summary is machine-generated.

Blacks have poorer bladder cancer survival rates compared to other ethnic groups, despite some improvements over time. These persistent racial disparities highlight the need for further investigation into care access and quality for Black patients.

More Related Videos

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Experiment Videos

Last Updated: May 30, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Area of Science:

  • Urology
  • Oncology
  • Public Health

Background:

  • Racial disparities in bladder cancer outcomes are documented, with Black individuals experiencing poorer survival.
  • Limited data exists on bladder cancer survival for other ethnic minority groups in the U.S.

Purpose of the Study:

  • To analyze 30-year trends in bladder cancer survival across White, Black, Hispanic, and Asian/Pacific Islander populations in the U.S.
  • To identify and compare ethnic variations in bladder cancer outcomes.

Main Methods:

  • Utilized Surveillance, Epidemiology, and End Results (SEER) cancer registry data from 1975-2005.
  • Analyzed a cohort of 163,973 White, 7,731 Black, 7,364 Hispanic, and 5,934 Asian/Pacific Islander patients diagnosed with transitional cell carcinoma of the bladder.
  • Estimated disease-specific 5-year survival rates stratified by ethnicity, stage, and grade.

Main Results:

  • Black patients presented with higher-stage bladder cancer compared to other ethnic groups.
  • Five-year disease-specific survival was consistently lower for Black patients (70.2%) versus Whites (82.8%), Hispanics (80.7%), and Asian/Pacific Islanders (81.9%).
  • A persistent survival disadvantage for Black patients was observed over the 30-year study period, irrespective of disease stage or grade.

Conclusions:

  • Significant ethnic disparities in bladder cancer survival persist between White and Black populations.
  • Survival rates for Hispanic and Asian/Pacific Islander groups were comparable to White individuals.
  • Further research into healthcare access, quality of care, and treatment decisions is crucial to address survival gaps in Black patients.